Potential Drugs for Treating COVID-19 Infection
| Author | Mehrdad Mohammadi | en |
| Author | Tim Sandle | en |
| Author | Sajad Rajabi | en |
| Author | Ahmad Khorshidi | en |
| Author | Ahmad Piroozmand | en |
| Orcid | Mehrdad Mohammadi [0000-0002-3683-5646] | en |
| Orcid | Tim Sandle [0000-0002-8304-8274] | en |
| Orcid | Sajad Rajabi [0000-0002-4619-5451] | en |
| Orcid | Ahmad Piroozmand [0000-0001-6392-0590] | en |
| Issued Date | 2020-10-10 | en |
| Abstract | The novel Coronavirus Disease 2019 (COVID-19) appeared as an emerging respiratory disease in December 2019 in Wuhan, Hubei province, China, and then spread rapidly worldwide, being declared a pandemic on March 11, 2020. Researchers are attempting to discover specifically designed antiviral treatments for COVID-19. Several therapeutic agents such as Interferon-α, Lopinavir/Ritonavir, Ribavirin, Chloroquine, Chloroquine phosphate, Hydroxychloroquine, Arbidol, Favipiravir, Remdesivir, Darunavir, Imatinib, Teicoplanin, Azithromycin, COVID-19 convalescent plasma, other potential antiviral drugs, and Chinese herbal agents are now being clinically studied to examine both pharmaceutical efficacy and safety for COVID-19 treatment in several countries. Some favorable results from these studies have been obtained to date. This review article summarizes and reiterates drugs that are potentially efficient against COVID-19. | en |
| DOI | https://doi.org/10.5812/iji.106243 | en |
| URI | https://brieflands.com/journals/iji/articles/106243 | en |
| Keyword | Novel Coronavirus | en |
| Keyword | COVID-19 | en |
| Keyword | Antiviral Drug | en |
| Keyword | Treatment | en |
| Publisher | Brieflands | en |
| Title | Potential Drugs for Treating COVID-19 Infection | en |
| Type | Review Article | en |